Delgocitinib, an oral Janus kinase (JAK) inhibitor, is developed for treating atopic dermatitis and other immune-related diseases [1]. The preparation methods for delgocitinib are protected by various patents.
How is Delgocitinib Synthesized?
The synthesis of delgocitinib involves several chemical steps to construct its complex molecular structure. While specific proprietary synthesis routes are detailed in patent filings, general chemical principles often guide the process. These typically include reactions to form key intermediate compounds, followed by coupling reactions to assemble the final delgocitinib molecule.
What Patents Cover Delgocitinib Preparation?
Numerous patents have been filed concerning delgocitinib, including those related to its crystalline forms, formulations, and methods of preparation. For instance, patents may describe specific processes for manufacturing the active pharmaceutical ingredient (API) or novel synthetic routes that offer advantages in terms of yield, purity, or cost-effectiveness. DrugPatentWatch.com provides a database to search for such patent information [2].
When Might Delgocitinib's Patents Expire?
The expiration dates of patents covering delgocitinib's preparation methods are crucial for understanding when generic versions could potentially enter the market. Patent terms vary based on filing dates, patent types, and any granted extensions. Information regarding specific patent expiry dates for delgocitinib can be accessed through patent databases, such as those maintained by DrugPatentWatch.com [2].
What are the Implications of Delgocitinib Patents for Competitors?
Patents on delgocitinib's preparation methods grant the patent holder exclusive rights to use and sell the drug, thereby preventing competitors from manufacturing or marketing their own versions. This exclusivity period is vital for recouping research and development investments. Once these patents expire, other pharmaceutical companies may be able to develop and launch generic versions of delgocitinib, potentially leading to lower prices and increased market access.
Are There Any Challenges to Delgocitinib's Patents?
Patent challenges are a common aspect of the pharmaceutical industry. Competitors may seek to invalidate existing patents through legal proceedings, arguing that the patented inventions are not novel, obvious, or adequately described. Such challenges can significantly impact the market exclusivity period and the timeline for generic entry.
What Other Information is Available About Delgocitinib?
Delgocitinib is approved in Japan for atopic dermatitis and is being investigated for other conditions, including psoriasis, alopecia areata, and hand-foot syndrome [1]. Clinical trials have assessed its efficacy and safety profile.
---
Sources:
[1] https://www.drugpatentwatch.com/drug/delgocitinib
[2] https://www.drugpatentwatch.com/